

Report on 2022 Lobbying Activities

The Board believes that it is in the best interest of our shareholders for McKesson to be an effective participant in the public policy process. The Board exercises oversight of McKesson's political and public policy activities. The Senior Vice President of Public Affairs has management responsibility for all political contributions, lobbying activities and related expenditures and consults with McKesson's senior business leaders and internal and external counsel to help ensure alignment between McKesson's political engagement activities, McKesson's public policy priorities and applicable law. The Senior Vice President of Public Affairs provides regular updates to the Board on such matters consisting of reports on public policy issues, political engagements, lobbying activities and corporate political contributions.

We disclose to our shareholders on an annual basis the aggregate dollars McKesson spends on certain lobbying activities as well as our general public policy priorities and lobbying efforts. The information below pertains to McKesson's lobbying activities during the calendar year ended December 31, 2022 (Calendar Year 2022).

Public Policy Priorities for Lobbying in Calendar Year 2022:

- Access to affordable medicines: McKesson is committed to bolstering community providers, which are often the lower cost, preferred setting of care for patients. We continue to invest in provider and patient tools to drive cost transparency and enable data-driven, shared decision-making between providers and patients.
- Connecting the healthcare landscape: We are committed to fostering a healthcare system that leverages technology to empower patients. McKesson is a member of the Healthcare Innovation Alliance, which works to harness the power of data and technology to improve patient care and speed up the development of potentially life-saving treatments.
- Promoting community healthcare providers: McKesson is committed to promoting diverse settings of care and supporting community healthcare providers. In communities across the country, pharmacists are often the first and most easily accessible health care provider. McKesson is a member of the Future of Pharmacy Care Coalition, ensuring equitable patient access to essential care and services by pharmacists.
- Addressing healthcare disparities: McKesson believes that health equity belongs to every patient and is committed to help reduce health disparities and inequities that impact patient access, quality of care and health outcomes.
- Protecting drug supply-chain security: McKesson supports public-private partnership of the strategic national stockpile and warm rotational managed inventory of essential medicines and medical products necessary for federal, state, and local emergency preparedness and response efforts.
- Advancing a comprehensive oncology and biopharma platform: We generate real-world data and evidence that accelerate oncology innovation, make clinical trials more accessible, deliver specialty therapy, conduct research, and help patients access and afford medicines. McKesson supports expanding clinical trial eligibility to increase patient diversity and removing barriers that prevent clinical trial completion.

Topics for Material Federal and State Lobbying Efforts in Calendar Year 2022

Central Fill for Prescription Drugs
Clinical Trial Patient Eligibility and Diversity
Healthcare disparities and Social Determinants of Health (SDoH)
Patient access, affordability, and adherence
Data Privacy, Information Blocking, and Interoperability
Drug Pricing
Direct and Indirect Remuneration (DIR) Fees
Emergency Preparedness and Response
Patient Benefit and Cost Pricing Transparency
Healthcare Equity and Racial Disparities
Medical Supply and Medicine Distribution Licensure
Pharmacist Payment, Recognition, and Reimbursement
Taxes

In Calendar Year 2022, our Public Affairs lobbying engagements with federal elected officials included activities regarding laws or regulations governing (a) patient equitable access to a pharmacy setting of care for testing, vaccination, and treatment of COVID, flu, and other respiratory illness and payment by Medicare to pharmacists for such services and (b) strengthening the nation's emergency preparedness and response for future public health emergencies and natural disasters through public-private partnerships with healthcare central distributors.

Lobbying efforts with state elected officials included activities regarding laws or regulations governing (a) access by patients and their prescribing clinician to the patient out-of-pocket outpatient prescription drug cost information as required to be included in the patient's electronic health record (EHR); (b) increasing access for independent pharmacists in select states, based on current regulations, to central fill services; (c) ensuring that pharmacy services administrative organizations (PSAOs) can continue to operate in the best interests of independent pharmacy; and (d) strengthening state response for future public health emergencies and natural disasters through public-private partnerships with healthcare central distributors.

Lobbying Spend

In Calendar Year 2022, McKesson spent approximately \$400,000 - \$700,000 with the below firms on external federal lobbying efforts and approximately \$850,000 - \$1,700,000 with the below firms on external state lobbying efforts:

Federal

Name of Firm	Payment Range
Todd Strategy	\$100,001 - \$200,000
Horizon Government Affairs	\$100,001 - \$200,000
Akin Gump	\$200,001 - \$300,000

State

Name of Firm	State	Payment Range
Triadvocates	Arizona	\$50,001 - \$100,000
Apra & Micheli	California	\$100,001 - \$200,000
Fernandez Cervantes	California	\$100,001 - \$200,000
Capitol Focus	Colorado	\$50,001 - \$100,000
Southern Group	Florida	\$50,001 - \$100,000
The JL Morgan Co	Georgia	\$50,001 - \$100,000
Strategic Partnership Alliance	Illinois	\$50,001 - \$100,000
Rotunda Group	Kentucky	\$50,001 - \$100,000
O’Neill & Associates	Massachusetts	\$50,001 - \$100,000
Capitol Resources	Mississippi	\$25,001 - \$50,000
Farrell Fritz	New York	\$50,001 - \$100,000
The Success Group	Ohio	\$50,001 - \$100,000
Capital Plus	Oklahoma	\$25,001 - \$50,000
Oxley & Associates	Oregon	\$50,001 - \$100,000
Bivens & Associates	Tennessee	\$50,001 - \$100,000
HillCo	Texas	\$100,001 - \$200,000
Macaulay Jamerson Satterlund and Sessa PC	Virginia	\$50,001 - \$100,000

We are a member of and make payments to certain health policy, 501(c)(4) and/or trade organizations that draft and support model legislation for purposes of advancing healthcare issues consistent with our public policy priorities. In Calendar Year 2022, those organizations and the amounts reported include the following:

Name of Organization	Amount Reported
National Community Pharmacists Association (NCPA)	\$9,975
American Disease Prevention Coalition	\$25,000
California Chronic Care Coalition	\$40,000
Health Innovation Alliance (HIA)	\$50,000
Community Oncology Alliance	\$80,000
Health Industry Distributors Association (HIDA)	\$110,790
Healthcare Leadership Council (HLC)	\$200,000
Business Roundtable (BRT)	\$350,000
Future of Pharmacy Care Coalition	\$500,000
National Association of Chain Drug Stores (NACDS)	\$774,560

Healthcare Distribution Alliance (HDA)	\$5,535,000
----------------------------------------	-------------

For more information regarding McKesson’s political activities, including our Political Engagement and Lobbying Policy, please visit <https://www.mckesson.com/About-McKesson/Public-Affairs/Political-Engagement/>.

###

McKesson requests information regarding annual spending with certain 501(c)(3), 501 (c)(4), and other professional or trade associations in which we may have membership or provide sponsorship but there is no direct or indirect lobbying activity. Entities that received \$25,000 or more during Calendar Year 2022 are listed on Attachment A.

Attachment A

Name of Organization	Amount
Urgent Care Association (UCA)	\$25,000
Independent Pharmacy Cooperative (IPC) Annual Conference	\$26,000
SMI Supply Chain	\$28,000
Healthcare Information and Management Systems Society (HIMSS)	\$30,000
National Association of Chain Drug Stores (NACDS) Foundation Dinner	\$30,000
Florida Health Care Association	\$31,250
Pharmacy Quality Alliance	\$34,900
American Pharmacy Cooperative Inc.	\$35,000
Future of Infusion Advisory Council	\$37,500
American Health Care Association (AHCA)	\$48,600
Drug Supply Chain Security Act (DSCSA) Governance Committee	\$50,000
State Privacy and Security Coalition	\$50,000
KLAS Research	\$50,500
National Council for Prescription Drug Programs (NCPDP)	\$52,000
Long Term Care (LTC) 100 Leadership Sponsorship	\$73,800
AA Home Care	\$75,000
American Pharmacy Services Corporation Foundation	\$75,000
National Association of Community Health Centers (NACHC)	\$85,000
Community Oncology Alliance	\$100,000
Healthcare Distribution Alliance (HDA) Research Foundation	\$100,000
The Leukemia and Lymphoma Society Inc/2022 Light the Night	\$100,000
Dallas Regional Chamber of Commerce	\$112,900
National Community Pharmacist Association (NCPA)	\$547,000